Europe's medicines regulator on Friday recommended approving the use of Moderna's COVID-19 vaccine in 12 to 17-year olds, paving the way for it to become the second shot okayed for adolescent use in the bloc.
The use of the vaccine, branded Spikevax, will be the same in adolescents as in people above 18 years, the European Medicines Agency (EMA) said, adding the vaccine produced a comparable antibody response to that seen in 18 to 25-year olds.
Vaccinating children has been considered important for reaching herd immunity against the novel coronavirus and in the light of the highly contagious Delta variant. Moderna in May said its vaccine was found to be safe and effective in teens.
EMA's safety committee said while common side effects in teenagers after vaccination were similar to those seen in older population, due to a smaller study size, the trial could not detect new uncommon side effects or estimate the risk of known ones such as myocarditis and pericarditis.
Trump says US will hit Iran 'very hard', take control of energy infrastructure
US confirms third strike on Indian-crewed tankers this week
US and Iran trade attacks for a second day, undermining shaky ceasefire
UK defence minister Healey quits, says PM Starmer's plans fail to keep country safe
Bahrain says debris from intercepted Iranian drones injures child, damages homes
Philippines launches probe into deaths of two athletes from top basketball team
Kuwait resumes airspace after brief closure due to Iranian attacks
Canada introduces legislation to ban social media for children under 16
